2009;53:401 8. 36. Sagie A, Schwammenthal E, Padial LR, et al. Determinants of functional tricuspid regurgitation in incomplete tricuspid valve closure: Doppler color flow study of 109 patients. J Am Coll Cardiol. 1994;24:446 53. 37. Lin G, Nishimura RA, Connolly HM, et al. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardio- verter-defibrillator leads. J Am Coll Cardiol. 2005;45:1672 5. 38. Alqahtani F, Berzingi CO, Aljohani S, et al. Contemporary trends in the use and outcomes of surgical treatment of tricuspid regurgitation. J Am Heart Assoc. 2017;6:e007597. 39. Jeganathan R, Armstrong S, Al-Alao B, et al. The risk and outcomes of reoperative tricuspid valve surgery. Ann Thorac Surg. 2013;95:119 24. 9. PULMONIC VALVE DISEASE 1. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the CLINICAL STATEMENTS AND GUIDELINES American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e698 800. 10. MIXED VALVE DISEASE 10.1. Diagnosis of Mixed VHD 1. Unger P, Rosenhek R, Dedobbeleer C, et al. Management of multiple valve disease. Heart. 2011;97:272 7. 2. Lee R, Li S, Rankin JS, et al. Fifteen-year outcome trends for valve surgery in North America. Ann Thorac Surg. 2011;91:677 84. 3. Venneri L, Khattar RS, Senior R. Assessment of complex multi-valve dis- ease and prosthetic valves. Heart Lung Circ. 2019;28:1436 46. 4. Iung B, Delgado V, Rosenhek R, et al. Contemporary presentation and management of valvular heart disease: the EURObservational Research Pro- gramme Valvular Heart Disease II Survey. Circulation. 2019;140:1156 69. 5. Unger P, Clavel MA, Lindman BR, et al. Pathophysiology and management of multivalvular disease. Nat Rev Cardiol. 2016;13:429 40. 10.2. Timing of Intervention for Mixed VHD 10.2.1. Intervention for Mixed AS and AR 1. 